- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
HBA Annual Conference Convenes in Washington D.C.
HBA’s Annual Conference was held in Washington, D.C. on November 5-6, with over 900 attendees-both men and women.
HBA’s ACE Awards kicked-off the conference activities with a luncheon event that honored the 2018 recipients-Pfizer, Insigniam, and KMPG for their women’s leadership initiatives. An ACE Awards retrospective also recognized the previous 12 recipients in appreciation for integrating women’s leadership programs into their organizational DNA.
Willard McCloud, global lead, diversity & inclusion and culture, Pfizer and Sabina Ewing, vice president, business technology, global women’s council chair, Pfizer
Jon Kleinman, partner, and Shideh Bina, founding partner
Topics at the conference ranged from “How Artificial Intelligence and Machine Learning are Transforming Healthcare” to “Find Your Mojo and Leverage Your Superpowers.” Lisa Henderson, Pharm Exec’s editorial director, spoke about Pharm Exec’s coverage and support of female industry leaders. Attendees also heard from mindfulness expert Susan O’Connor, a former executive at Pfizer, who shared her approach on how to balance personal well-being with the demands of work life. Lisa Bodell, founder, future think, closed out the conference sharing best practices on how to eliminate complexity from the daily grind.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
